In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Influenza vaccines developer Vivaldi Biosciences brought in $18.85mm through a financing of Series A convertible preferred shares co-led by Bay City Capital and NGN Capital, which were joined by the New York City Investment Fund and Alexandria Real Estate Equities. The company could bring the total raised to $23mm if it achieves certain milestones.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?